These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22829886)

  • 1. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.
    Lautz TB; Jie C; Clark S; Naiditch JA; Jafari N; Qiu YY; Zheng X; Chu F; Madonna MB
    PLoS One; 2012; 7(7):e40816. PubMed ID: 22829886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
    Zheng X; Naiditch J; Czurylo M; Jie C; Lautz T; Clark S; Jafari N; Qiu Y; Chu F; Madonna MB
    Cell Death Dis; 2013 Jul; 4(7):e740. PubMed ID: 23887631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
    More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
    Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
    Huang JM; Sheard MA; Ji L; Sposto R; Keshelava N
    Mol Cancer Ther; 2010 Dec; 9(12):3289-301. PubMed ID: 21159612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
    Slovak ML; Hoeltge GA; Dalton WS; Trent JM
    Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat.
    Falkenberg KJ; Gould CM; Johnstone RW; Simpson KJ
    Sci Data; 2014; 1():140017. PubMed ID: 25977774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
    Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
    Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
    Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
    Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
    Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
    BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.
    Gangoda L; Keerthikumar S; Fonseka P; Edgington LE; Ang CS; Ozcitti C; Bogyo M; Parker BS; Mathivanan S
    Oncotarget; 2015 May; 6(13):11175-90. PubMed ID: 25883214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal change and drug resistance in neuroblastoma.
    Naiditch JA; Jie C; Lautz TB; Yu S; Clark S; Voronov D; Chu F; Madonna MB
    J Surg Res; 2015 Jan; 193(1):279-88. PubMed ID: 25128389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.